Limits...
Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY - J. Exp. Clin. Cancer Res. (2012)

Bottom Line: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway.SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues.Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China.

ABSTRACT

Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.

Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations.

Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P=0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P<0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC.

Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SOX9-expressing (bold line) versus high SOX9-expressing tumors (dotted line). The cumulative 3-year survival rate was 65.9% in the low SOX9 expression group (n = 44), whereas it was only 24.5% in the high SOX9 expression group (n = 45).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3313873&req=5

Figure 4: Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SOX9-expressing (bold line) versus high SOX9-expressing tumors (dotted line). The cumulative 3-year survival rate was 65.9% in the low SOX9 expression group (n = 44), whereas it was only 24.5% in the high SOX9 expression group (n = 45).

Mentions: The statistical analysis presented in Table 2 revealed an inverse correlation between SOX9 level and patient survival (P = 0.040). Spearman analysis also showed a correlation coefficient of -0.239 (P = 0.024; Table 3) between SOX9 and patient survival. Log-rank test and Kaplan-Meier analysis were also applied to evaluate further the effect of SOX9 expression and histological staging of lung cancer on survival. The log-rank test showed that the expression level of SOX9 protein in NSCLC was correlated significantly with patients' survival time (P < 0.001), with a correlation coefficient of -0.262 (Figure 4; Table 4). As shown in Figure 4, the cumulative 3-year survival rate was 65.9% in the low-SOX9 expression group (n = 44), and 24.5% in the high-SOX9 expression group (n = 45). The multivariate survival analysis shown in Table 4 indicated that SOX9 expression level was an independent prognostic factor in the assessment of patient outcomes.


Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY - J. Exp. Clin. Cancer Res. (2012)

Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SOX9-expressing (bold line) versus high SOX9-expressing tumors (dotted line). The cumulative 3-year survival rate was 65.9% in the low SOX9 expression group (n = 44), whereas it was only 24.5% in the high SOX9 expression group (n = 45).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3313873&req=5

Figure 4: Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SOX9-expressing (bold line) versus high SOX9-expressing tumors (dotted line). The cumulative 3-year survival rate was 65.9% in the low SOX9 expression group (n = 44), whereas it was only 24.5% in the high SOX9 expression group (n = 45).
Mentions: The statistical analysis presented in Table 2 revealed an inverse correlation between SOX9 level and patient survival (P = 0.040). Spearman analysis also showed a correlation coefficient of -0.239 (P = 0.024; Table 3) between SOX9 and patient survival. Log-rank test and Kaplan-Meier analysis were also applied to evaluate further the effect of SOX9 expression and histological staging of lung cancer on survival. The log-rank test showed that the expression level of SOX9 protein in NSCLC was correlated significantly with patients' survival time (P < 0.001), with a correlation coefficient of -0.262 (Figure 4; Table 4). As shown in Figure 4, the cumulative 3-year survival rate was 65.9% in the low-SOX9 expression group (n = 44), and 24.5% in the high-SOX9 expression group (n = 45). The multivariate survival analysis shown in Table 4 indicated that SOX9 expression level was an independent prognostic factor in the assessment of patient outcomes.

Bottom Line: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway.SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues.Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China.

ABSTRACT

Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.

Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations.

Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P=0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P<0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC.

Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.

Show MeSH
Related in: MedlinePlus